Your Strategic Route to the Iraqi Pharmaceutical Market
Iraq is one of the region's most commercially attractive pharmaceutical markets — but it rewards experienced coordination across regulatory, pricing, importation, logistics, and promotion. That coordination is what we do.
A $4.6 Billion Market Growing at 12.5% Annually
Source: IQVIA / Ministry of Health reports 2024. Figures editable — review periodically against validated sources.
What makes Iraq attractive
- Major government investment in healthcare infrastructure and new hospitals
- Rising demand for chronic-disease management (diabetes, CVD)
- Growing demand for oncology, fertility, respiratory, and specialized therapies
- Expanding hospital and pharmacy networks with increasing insurance coverage
- Strategic gateway position for regional pharmaceutical trade
What makes it demanding
- Multi-step regulatory requirements: site registration before product registration
- Pricing approval, import permits, and customs coordination
- Parallel public (KIMADIA tender) and private market channels
- Scientific promotion expectations from a large prescriber base
- Pharmacovigilance and lifecycle obligations after launch
Five Phases from Assessment to Sustainable Growth
Opportunity Assessment
- Portfolio review
- Therapeutic-area assessment
- Competitor mapping
- Price benchmarking
- Forecasting
- Regulatory feasibility
Partnership Structuring
- Distribution model
- Exclusivity terms
- Brand promotion plan
- MAH responsibilities
- Forecast & MOQ commitments
- Marketing commitment
- Regulatory responsibilities
Regulatory Preparation includes site registration
- Manufacturing-site registration
- Dossier review (CTD)
- Legalization
- Samples & laboratory testing
- Labeling review
- Pricing application
- Submission & MOH follow-up
Commercial Launch importation & permits
- Importation & customs
- Warehousing & cold chain
- Nationwide distribution
- Sales-force training
- KOL engagement
- Launch campaign
- Pharmacy & hospital activation
Growth & Lifecycle pricing & renewals
- Forecast review
- Additional SKUs
- Geographic expansion
- Tender opportunities
- Indication expansion
- Renewals & variations
- Market-share optimization
Market-Entry FAQ
Yes. Iraqi MOH registration follows a site-first sequence: the manufacturing site is registered, then individual products. Our RA team prepares and manages both files in parallel where possible to compress timelines.
Yes. We support local-representation and MAH-support models, covering regulatory duties, pharmacovigilance coordination, importation, and commercial execution — structured contractually to your compliance requirements.
Iraq operates parallel channels: KIMADIA-led public procurement supplying government hospitals, and a large private retail/hospital market. We maintain an active presence in both and advise partners on channel strategy per product.
Portfolio prioritization, competitor and price benchmarking, regulatory feasibility per product, demand forecast, and a recommended entry structure — delivered as a structured document for your business-development team.